ArticleUrology2016
Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Article in Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Peyronie's disease patients with pain: a post hoc analysis of the IMPRESS I/II studies.Translational andrology and urology · 2026Article
- Efficacy and safety of collagenaseSexual medicine · 2026Article
- Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation.International journal of impotence research · 2025Review
- Late-Onset Penile Fracture After CollagenaseCase reports in urology · 2025Article
- Expanded Utilization of Intralesional Therapies for Treatment of Peyronie's Disease.Research and reports in urology · 2023Review
- Predictors of Curvature Improvement in Men With Peyronie's Disease Treated With Intralesional Collagenase Clostridium Histolyticum.The journal of sexual medicine · 2022Article
- Intralesional collagenaseTranslational andrology and urology · 2022Article
- Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie's Disease: A Claims-Based Analysis (2009-2019).Sexual medicine · 2022Article
- Global Perspective on the Management of Peyronie's Disease.Frontiers in reproductive health · 2022Review
- Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie's Disease is not associated with worsening of erectile function.International journal of impotence research · 2022Article
- Predictors of Pursuing Intralesional Xiaflex in Peyronie's Disease Patients.The journal of sexual medicine · 2021Article
- "Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities.International journal of impotence research · 2021Article
- Collagenase clostridium histolyticum is no longer available in Europe: what does this mean for our patients with Peyronie's Disease?International journal of impotence research · 2021Article
- The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy.Current urology reports · 2021Review
- Treatment Trends and Cost Associated With Peyronie's Disease.Sexual medicine · 2020Article
- Efficacy of Collagenase Clostridium histolyticum (XiapexClinical drug investigation · 2020Article
- Minimally invasive therapies for Peyronie's disease: the current state of the art.Translational andrology and urology · 2020Review
- Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond.World journal of urology · 2020Review
- A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease results in reduced procedural morbidity using a standardized hematoma classification rubric.World journal of urology · 2020Article
- Management of Peyronie's disease with collagenase Clostridium histolyticum in the acute phase.World journal of urology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report on an early adopter series of collagenase Clostridium histolyticum (CCh) for Peyronie's disease (PD). Postapproval studies of CCh have been anticipated after recent Food and Drug Administration authorization of its use for men with PD as definitive and durable nonsurgical interventions have been long desired. MATERIALS AND
methodsFrom May 2014 to October 2015, a database consisting of PD patients with >30° of penile curvature received CCh from a single provider at a single institution. Objective penile curvature measurements and deformity directions were assessed pre- and posttreatment. Using the validated Peyronie's Disease Questionnaire (PDQ), changes in subjective symptoms of intercourse ability, penile pain, and bother were also noted.
resultsWe followed 49 unique PD patients treated with CCh. Mean follow-up was 183 days with a median of 6 injections over 3 cycles performed per patient. The mean pretreatment penile curvature was 49.3 degrees. Curvature was reduced by 15.4 degrees (32.4%, P < .01) after therapy. There were 10 out of 22 patients who regained ability to perform vaginal intercourse. Subjectively, there was an improvement in the ability to perform intercourse (29.1% improvement, P < .01) and bother symptoms (mean decrease 43.2%, P < .01), but no significant changes in penile pain (P = .89). Five notable bleeding events (10.2%) were noted, including 1 penile fracture requiring operative exploration.
conclusionCCh use for PD yielded improvements in penile curvature, subjective intercourse, and bother symptoms. Further postanalysis studies of greater follow-up are needed to assess long-term durability, efficacy, and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.